- Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose.
- Based on topline results from the Phase 3 PHOENIX trial of AMX0035 in ALS, Amylyx has started a process with the FDA and Health Canada of voluntarily discontinuing the marketing authorizations for.
Reported $380.8 million in net product revenue for the full year 2023, including $108.4 million in the fourth quarter
Delivered $49.3 million in net income for the full year 2023, including $4.7.
Amylyx Pharmaceuticals, Inc. today announced that two abstracts detailing next steps in the development of the Company’s investigational antisense oligonucleotide , AMX0114, for the potential.